Stifel analyst Rick Wise lowered the firm’s price target on Boston Scientific (BSX) to $90 from $110 and keeps a Buy rating on the shares after the firm surveyed 60 physicians to help quantify CHAMPION-AF clinician expectations and the potential impact on LAAC growth ahead of the late breaking CHAMPION-AF left-atrial-appendage-closure clinical trial results that are set to read-out at the American College of Cardiology on March 28.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
- FDA inspectors found Boston Scientific pacemakers had battery issues, NYT says
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Boston Scientific Faces Investor Lawsuit Alleging Misleading Statements About Electrophysiology Growth
- Boston Scientific price target lowered to $92 from $95 at Truist